Therapeutic interest is currently focusing on GSK3β, Cdk5, MAPK, MARK4, ROCK, Ca2+/CaM-dependent protein kinase II (CaMKII) and others that are involved in Tau hyperphosphorylation, especially in AD [84]. This evidence concerns the gene MAPT and Alzheimer disease.